EQL Pharma AB (publ)

OM:EQL Stock Report

Market Cap: SEK 1.6b

EQL Pharma Valuation

Is EQL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of EQL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: EQL (SEK54.2) is trading above our estimate of future cash flow value (SEK4.54)

Significantly Below Future Cash Flow Value: EQL is trading above our estimate of future cash flow value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EQL?

Key metric: As EQL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EQL. This is calculated by dividing EQL's market cap by their current earnings.
What is EQL's PE Ratio?
PE Ratio54.5x
EarningsSEK 29.34m
Market CapSEK 1.56b

Price to Earnings Ratio vs Peers

How does EQL's PE Ratio compare to its peers?

The above table shows the PE ratio for EQL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average33.3x
ASKER Asker Healthcare Group
53.7x24.87%SEK 24.3b
HUM Humana
9.2x13.17%SEK 2.2b
CARA Carasent
45.6x31.19%SEK 1.6b
SUS Surgical Science Sweden
24.7x28.99%SEK 1.6b
EQL EQL Pharma
54.5x66.27%SEK 1.6b

Price-To-Earnings vs Peers: EQL is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the peer average (33.3x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does EQL's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EQL 54.5xIndustry Avg. 18.8xNo. of Companies10PE01632486480+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EQL is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the European Healthcare industry average (18.8x).

Price to Earnings Ratio vs Fair Ratio

What is EQL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EQL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio54.5x
Fair PE Ratio49.2x

Price-To-Earnings vs Fair Ratio: EQL is expensive based on its Price-To-Earnings Ratio (54.5x) compared to the estimated Fair Price-To-Earnings Ratio (49.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

SEK 80
Fair Value
32.3% undervalued intrinsic discount
1
Number of Analysts

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/17 22:20
End of Day Share Price 2026/03/17 00:00
Earnings2025/12/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

EQL Pharma AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdDNB Carnegie Commissioned Research